Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Patel, Keyur P., Newberry, Kate J., Luthra, Rajyalakshmi, Jabbour, Elias, Pierce, Sherry, Cortes, Jorge, Singh, Rajesh, Mehrotra, Meenakshi, Routbort, Mark J., Luthra, Madan, Manshouri, Taghi, Santos, Fabio P., Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528066/
https://ncbi.nlm.nih.gov/pubmed/26124496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-633404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados